Thyroid Cancer Patients May Get Help from New Drug Lenvima Instead of Radiotherapy
Vittorio Hernandez | | Feb 14, 2015 05:10 AM EST |
(Photo : REUTERS) The FDA headquarters at Silver Spring, Maryland.
A new drug to treat thyroid cancer patients whose conditions continue to worsen despite undergoing radioactive iodine therapy is now available. The U.S. Food and Drug Administration (FDA) approved on Friday the oral drug Lenvima.
Sold under the generic name lenvatinib, the new medication for progressive thyroid cancer delayed the progress of the disease almost five times longer compared to those with recurring tumors who used placebo, according to the result of a clinical trial, reports Philly.com.
Like Us on Facebook
It battles the thyroid cancer by deterring the growth of new blood vessels that could help feed the cancer. Those who used placebo in the study only had four months delay in progression compared to 18 months for those who took Lenvima.
Dr. Steven Sherman, leader of the study and professor and chair of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center, said that prior to the approval of lenvatinib by the FDA, the only treatment available to people suffering from thyroid cancer was radioactive iodine.
But more than 50 percent of patients don't respond to radioactive iodine, and sufferers tend to develop resistance to the treatment over time, Sherman said.
Pharmaceutical firm Eisai funded the research that was published in the February 12 issue of New England Journal of Medicine. The research had almost 400 patients from 21 nations.
But like many drugs, Lenvima has some side effects such as heart failure, formation of blood clot, damage to liver and kidney, headache, confusion, seizures and visual changes.
Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said these side effects on a patient's quality of life should be weighed against overall survival, which unfortunately remains unknown so far.
According to the FDA, almost 63,000 Americans are suffering from thyroid cancer and 1,890 died from it in 2014.
FDA approved Lenvima about two months ahead of its prescription drug user fee goal date of April 14, 2015 because it was reviewed by the regulator under its priority review program.
Tagsthyroid cancer, Lenvima, Lenvatinib, Radioactive Iodine Therapy
©2015 Chinatopix All rights reserved. Do not reproduce without permission
EDITOR'S PICKS
-
Did the Trump administration just announce plans for a trade war with ‘hostile’ China and Russia?
-
US Senate passes Taiwan travel bill slammed by China
-
As Yan Sihong’s family grieves, here are other Chinese students who went missing abroad. Some have never been found
-
Beijing blasts Western critics who ‘smear China’ with the term sharp power
-
China Envoy Seeks to Defuse Tensions With U.S. as a Trade War Brews
-
Singapore's Deputy PM Provides Bitcoin Vote of Confidence Amid China's Blanket Bans
-
China warns investors over risks in overseas virtual currency trading
-
Chinese government most trustworthy: survey
-
Kashima Antlers On Course For Back-To-Back Titles
MOST POPULAR
LATEST NEWS
Zhou Yongkang: China's Former Security Chief Sentenced to Life in Prison
China's former Chief of the Ministry of Public Security, Zhou Yongkang, has been given a life sentence after he was found guilty of abusing his office, bribery and deliberately ... Full Article
TRENDING STORY
-
China Pork Prices Expected to Stabilize As The Supplies Recover
-
Elephone P9000 Smartphone is now on Sale on Amazon India
-
There's a Big Chance Cliffhangers Won't Still Be Resolved When Grey's Anatomy Season 13 Returns
-
Supreme Court Ruled on Samsung vs Apple Dispute for Patent Infringement
-
Microsoft Surface Pro 5 Rumors and Release Date: What is the Latest?